enoksaparyn sodium – Anfiber injection for 10 thousand anti-Xa ME /ml 0.400 ml ampoules 10 pcs

$57.00

Description

Release form

Injection

Pharmacological action

Antifiber – direct-acting anticoagulant. It belongs to the group of low molecular weight heparins (with a molecular weight of about 4,500 daltons). It has an antithrombotic effect.

Has a pronounced activity against factor Xa and weak activity against factor IIa. In contrast to unfractionated standard heparin, antiplatelet activity is more pronounced than anticoagulant activity. It does not affect platelet aggregation.

Pharmacokinetics

When s / c administration is rapidly and almost completely absorbed from the injection site. The peak anti-Xa activity of enoxaparin in plasma is reached after 3-5 hours, which corresponds to a concentration of 1.6 μg / ml after administration of 40 mg. Enoxaparin Vd corresponds to blood volume.

Enoxaparin sodium is slightly metabolized in the liver to form inactive metabolites.

T1 / 2 – about 4 hours. Anti-Xa plasma activity is determined within 24 hours after a single injection. It is excreted in the urine, unchanged and in the form of metabolites.

In patients with renal failure and in the elderly, an increase in T1 / 2 to 5-7 hours is possible, but correction of the dosage regimen is not required.

During hemodialysis, elimination of enoxaparin does not change.

Indications

Prevention of thromboembolism, especially in orthopedic practice and general surgery

treatment of deep vein thrombosis prevention of hypercoagulation in the extracorporeal circulation system during hemodialysis.

Treatment of unstable angina and myocardial infarction without an abnormal Q wave on an ECG (in combination with acetylsalicylic acid).

Contraindications

Conditions with a high risk of developing uncontrolled bleeding (including gastrointestinal ulceration, recent hemorrhagic stroke), increased sensitivity to enoxaparin.

Use during pregnancy and lactation

Use during pregnancy is not recommended.

If necessary, use of enoxaparin sodium during lactation, breast-feeding should be discontinued.

Special instructions

Do not inject in oil. Low molecular weight heparins are not interchangeable.

If there is a history of thrombocytopenia induced by heparin, enoxaparin sodium can be used only in cases of emergency.

Use with caution in patients with a potential risk of bleeding (including with hypocoagulation conditions, a history of gastric ulcer and duodenal ulcer), ischemic cerebrovascular accident, uncontrolled severe arterial hypertension, diabetic retinopathy, repeated neurological or ophthalmological operations, as well as in patients with severe liver diseases.

Not recommended for spinal / epidural anesthesia.

Before and during treatment, platelet count in the peripheral blood should be regularly monitored. If this indicator decreases by 30-50% of the initial value, enoxaparin sodium should be immediately canceled and appropriate therapy should be prescribed.

Before starting use, you should cancel the funds that could potentially affect hemostasis if this is not possible, then simultaneous therapy is carried out under close monitoring of coagulation parameters.

Composition of

1 ml of the solution contains:

Active ingredient:

naphthyne hydrochloride 10 mg

Excipients:

propylene glycol – 50 mg

ethanol (95% ethyl alcohol) – 400 mg srdlpf 1 pdf 1 ml srdlkf dp48 1 pdf dpfp48 dkrf48 ml of solution contains:

active substance:

enoxaparin sodium 100 mg (10,000 anti-XA IU)

excipients:

d / i water.

Dosage and administration

Dosing regimen is individual.

Enter subcutaneously in the anterolateral or posterolateral region of the abdominal wall at the level of the belt.

Side effects

From the blood coagulation system: rarely – moderate asymptomatic thrombocytopenia.

From the liver: rarely – a reversible increase in the level of activity of liver enzymes.

Allergic reactions: rarely – skin rash, itching.

Local reactions: rarely – an inflammatory reaction in isolated cases – necrosis.

Drug interaction

When used concomitantly with drugs that affect hemostasis (salicylates, other NSAIDs, dextran 40, ticlopidine, glucocorticosteroids, thrombolytics, anticoagulants), the anticoagulant effect of sodium enoxiparin is enhanced, and hemorrhagic complications may develop.

prescription uska IZ

pharmacy prescription

dosage form

injection

Appointment

Adult, Pregnant doctor’s appointment, Adult doctor’s appointment

Indications

Infarction And Stroke Prevention, Angina, Heart Failure precision, Thrombosis prevention, Prevention of acute myocardial infarction, Prevention of thromboembolism